Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsGUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions Ltd (“Bio-Thera”) announced today that ithas reached a licensing agreement with Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) for BAT1706, its bevacizumab biosimilar, under which Cipla will have exclu...
Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company has filed an Investigational New Drug Application (IND) with the China National Medical Products Administration (NMPA) for the Comp...
Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2018 San Antonio Breast Cancer Symposium (SABCS) taking place December 4 - 8, 2018 in San Antonio, ...
